[CAS NO. 41179-33-3] CMPD1
PRODUCTS SPECIFICATIONS [41179-33-3]
DESCRIPTION [41179-33-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 349.40 |
| Molecular Formula | C22H20FNO2 |
| SMILES | O=C(NC1=CC=C(O)C=C1)CCCC2=CC=C(C3=CC=CC=C3F)C=C2 |
Summary
IC50 & Target
Ki app : 330 nM (MK2 phosphorylation) [2]
In Vitro
CMPD1 does not inhibit p38 MAPK-mediated phosphorylation of other two substrates, MBP and ATF2
[1]
.
CMPD1 induced mitotic arrest and apoptosis in U87 cells
[1]
.
CMPD1 inhibits tubulin polymerisation in glioblastoma cells
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 286.20 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8620 mL | 14.3102 mL | 28.6205 mL |
| 5 mM | 0.5724 mL | 2.8620 mL | 5.7241 mL |
| 10 mM | 0.2862 mL | 1.4310 mL | 2.8620 mL |
References
- [1] Gurgis F, et al. Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. Cell Death Discov. 2015 Sep 7;1:15028.
- [2] Davidson W, er al. Discovery and characterization of a substrate selective p38alpha inhibitor. Biochemistry. 2004 Sep 21;43(37):11658-71.
- [3] Phoa AF, et al. Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochem Pharmacol. 2015 Dec 15;98(4):587-601.
